DSM inks major commercial agreement for its XD technology

Wednesday, June 20, 2012 11:55 AM

DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, has signed a commercial agreement for contract manufacturing services using its proprietary XD high cell density process technology with a major pharma company.

"We are proud to announce that a major pharma company has chosen DSM's services and technology for three of their leading antibody pipeline projects for different indications," said Karen King, president of DSM Biologics. "We will apply our XD technology in combination with our technology portfolio, and manufacture from our Groningen, The Netherlands, and Brisbane, Australia facilities."  

XD technology is a highly intensified cell culture process with titer achievement 5-to-15 times higher compared to current standard biomanufacturing processes. It is widely applicable for multiple products including proteins, fusion proteins and antibodies, and has been successfully employed across the full spectrum of mammalian cell systems.

DSM will complete the process development and commercial manufacturing for the products. These projects will be performed at the R&D and manufacturing site in Groningen and at new operations in Brisbane. The commercial demand will be met from Brisbane on a 500-liter XD production line. Typically XD has increased product titers by a factor of 5-to-15 times which means a 500L bioreactor can provide a DSM client with the same amount of drug substance as a 5000L stainless steel bioreactor at an overall lower cost.

Brisbane is DSM's blueprint for its 'biologics plant of the future' for biopharmaceuticals manufacturing. DSM's proprietary technologies drive down cost, processing times and capital requirements to meet market demand for life saving medications.  XD® has also shown impressive results for biosimilars and ethical drugs with respect to both volume and product quality.

Financial terms were not disclosed.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs